NVNO
Income statement / Annual
Last year (2024), enVVeno Medical Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, enVVeno Medical Corporation's net income was -$21.82 M.
See enVVeno Medical Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$31.24 K |
$186.55 K |
$422.11 K |
$785.91 K |
$0.00 |
| Cost of Revenue |
$528.00 K
|
$546.00 K
|
$525.00 K
|
$452.91 K
|
$383.97 K
|
$0.00
|
$0.00
|
$558.87 K
|
$961.47 K
|
$125.42 K
|
| Gross Profit |
-$528.00 K
|
-$546.00 K
|
-$525.00 K
|
-$452.91 K
|
-$383.97 K
|
$0.00
|
$0.00
|
-$136.76 K
|
-$175.56 K
|
-$125.42 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.32
|
-0.22
|
0
|
| Research and Development Expenses |
$12.25 M
|
$13.58 M
|
$9.91 M
|
$5.73 M
|
$4.25 M
|
$2.21 M
|
$1.24 M
|
$649.74 K
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.05 M
|
$11.11 M
|
$14.49 M
|
$10.71 M
|
$4.50 M
|
$4.51 M
|
$6.35 M
|
$5.32 M
|
$4.48 M
|
$1.16 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$23.30 M
|
$24.69 M
|
$24.41 M
|
$16.44 M
|
$8.75 M
|
$6.72 M
|
$7.59 M
|
$5.97 M
|
$4.48 M
|
$1.16 M
|
| Cost And Expenses |
$23.83 M
|
$25.24 M
|
$24.93 M
|
$16.89 M
|
$9.14 M
|
$7.12 M
|
$7.72 M
|
$6.53 M
|
$5.45 M
|
$1.29 M
|
| Interest Income |
$389.00 K
|
$180.00 K
|
$161.00 K
|
$18.71 K
|
$3.74 K
|
$50.85 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$933.00
|
$6.86 M
|
$1.92 M
|
$57.89 K
|
$88.52 K
|
| Depreciation & Amortization |
$528.00 K
|
$546.00 K
|
$525.00 K
|
$452.91 K
|
$383.97 K
|
$396.67 K
|
$133.42 K
|
$139.21 K
|
$151.17 K
|
$125.42 K
|
| EBITDA |
-$21.29 M |
-$22.97 M |
-$24.14 M |
-$16.07 M |
-$8.75 M |
-$7.23 M |
-$6.05 M |
-$5.73 M |
-$5.38 M |
-$1.16 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-231.34
|
-32.42
|
-13.58
|
-6.84
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-226.82
|
-40.39
|
-14.46
|
-5.93
|
0
|
| Total Other Income/Expenses Net |
$2.01 M
|
$1.72 M
|
$263.00 K
|
$364.68 K
|
-$360.00
|
-$538.91 K
|
-$5.51 M
|
-$1.69 M
|
-$929.08 K
|
-$88.35 K
|
| Income Before Tax |
-$21.82 M
|
-$23.52 M
|
-$24.67 M
|
-$16.53 M
|
-$9.14 M
|
-$7.63 M
|
-$13.04 M
|
-$7.79 M
|
-$5.59 M
|
-$1.38 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-244.07
|
-69.91
|
-18.46
|
-7.11
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$21.82 M
|
-$23.52 M
|
-$24.67 M
|
-$16.53 M
|
-$9.14 M
|
-$7.63 M
|
-$13.04 M
|
-$7.79 M
|
-$5.89 M
|
-$1.60 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-244.07
|
-69.91
|
-18.46
|
-7.49
|
0
|
| EPS |
-1.27 |
-1.91 |
-2.2 |
-1.9 |
-7.54 |
-12.1 |
-34.83 |
-20.1 |
-7.72 |
-3.66 |
| EPS Diluted |
-1.27 |
-1.91 |
-2.2 |
-1.9 |
-7.54 |
-12.1 |
-34.83 |
-20.1 |
-7.72 |
-3.66 |
| Weighted Average Shares Out |
$17.14 M
|
$12.30 M
|
$11.23 M
|
$8.68 M
|
$1.29 M
|
$630.42 K
|
$374.50 K
|
$387.69 K
|
$438.72 K
|
$438.72 K
|
| Weighted Average Shares Out Diluted |
$17.14 M
|
$12.30 M
|
$11.23 M
|
$8.68 M
|
$1.29 M
|
$630.42 K
|
$374.50 K
|
$387.69 K
|
$438.72 K
|
$438.72 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
